Drugs / SKB107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07087197 | Aug 2025 → Oct 2027 expected | metastatic neoplasm | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-03-25 | Klus Pharma Inc. | Regulatory Kelun-Biotech’s Radionuclide-Drug Conjugate (RDC) SKB107 Receives IND Approval from NMPA kluspharma.com ↗
the Company has received a clinical trial notice approving the investigational new drug application for a radionuclide-drug conjugate (RDC) drug SKB107 (formerly TBM-001) from the Center for Drug Evaluation of the National Medical Products Administration. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-25 | Klus Pharma Inc. | Kelun-Biotech’s Radionuclide-Drug Conjugate (RDC) SKB107 Receives IND Approval from NMPA kluspharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07087197 ↗ |